Article

Bladder cancer

Presented by Gary D. Grossfeld, MD, Marin Urology Medical Group, Greenbrae,CA.

Related Videos
1 expert is featured in this series.
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
2 experts are featured in this series.
Key Benefits of PET in ccRCC Risk Stratification
4 experts in this video
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
2 experts are featured in this series.
Early Detection of ccRCC
1 expert is featured in this series.
Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Study findings highlight gender gaps in oncology authorship and citation
NMIBC Treatment Decisions in the Age of BCG Shortages
NMIBC Treatment Decisions in the Age of BCG Shortages
Current Standards of Care and Shifting Strategies in NMIBC
Current Standards of Care and Shifting Strategies in NMIBC
Related Content
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
June 2nd 2025

Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC

Hannah Clarke
Lower-dose abiraterone acetate was found to demonstrate comparable efficacy to standard-dose abiraterone.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Survey: New NMIBC treatments face slow uptake
June 2nd 2025

Survey: New NMIBC treatments face slow uptake

Benjamin P. Saylor
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
FDA updates in urology: May 2025
June 2nd 2025

FDA updates in urology: May 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from May 2025.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
June 1st 2025

NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

Benjamin P. Saylor
The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.
© 2025 MJH Life Sciences

All rights reserved.